

Press Release

Source: MBC Pharma Inc.

MBC Pharma Inc. Awarded a SBIR Phase II Grant to Investigate Novel Compounds for Prostate Cancer

Aurora, CO – August 27, 2010 - MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an \$1,795,054 phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health (NIH). MBC will use this 2-year grant to further expand their discovery pipeline of bone-targeted chemotherapeutics for the treatment of cancer induced bone disease. The work will focus on the synthesis and efficacy testing of novel bone-targeted conjugates of agents with known activities against prostate cancers.

“New therapies are truly needed for the patients enduring the morbidity caused by cancer induced bone disease. MBC has used a combination of private investment and NIH grant money to demonstrate a novel platform technology can effectively produce compounds with efficacy in a number of animal models of cancer induced bone disease. This new funding will allow us to test a number of exciting new compounds with great potential to address metastatic prostate cancer and possibly primary disease as well, ”said Dr. Alexander Karpeisky, CSO and the Principal Investigator on the SBIR grant. “The SBIR program continues to be a great help to our efforts and we are grateful for the support and recognition of the potential benefit that MBC technology can offer for many types of bone disease. Researchers continue to report new ways that the bone environment proves critical to cancer development. Targeting the cancer cells in the bone environment, we think, will prove critical to treating not only the bone localized cancer but to potentially inhibiting overall metastases and halting further cancer development,” added Dr. Shawn Zinnen, VP of R&D.

About MBC Pharma

MBC Pharma is a privately held pre-clinical-stage pharmaceutical company developing bone targeted therapeutics for serious diseases and conditions of bone with an oncology focus. MBC Pharma is planning to submit its first IND application in the first quarter of 2011 and subsequently initiate Phase I trials with its first-in-class compound MBC-11.

For information on MBC Pharma please contact Dr. Alexander Karpeisky at 720-859-4041 or Dr. Shawn Zinnen at 720-859-4040

MBC Pharma, Inc.

<http://www.mbcpharma.com>